In his first nine months in office, President Donald Trump has issued a flurry of executive actions in the name of lowering prescription drug costs in the United States. Yet, Americans continue to pay three times as much as our peers for prescription drugs. Why is there a gap between the president’s rhetoric and realized reform?
Almost all Americans agree that prescription costs are too high, and the president is rightly focusing on this issue as a cornerstone of his second term. But while the president has mastered the headlines, he has not mastered the policy. His latest proposals like the most favored nation movement or pharmaceutical tariffs promise savings while quietly driving up prices and jeopardizing access to essential medicine.
I wrote about the gap between Trump’s flashy headlines and a true, pragmatic roadmap for prescription drug policy last weekend for the Worcester Telegram and Gazette. You can read more here.
